IL-6 has been shown to trigger cancer cell proliferation by activating the JAK/STAT3, ERK1/2, and STAT3/NFĸB pathways in breast cancer cells and can lead to increased levels of IL-23, which is a link between tumor-associated inflammation and tumor immune evasion and can also activate NF-κB signaling (75). Here, STAT3 is linked to cancer.